11th Mentored Paper (Winter 2024)

Topics

MPI 11.1: What are the major stresses that drive the formation, progression, and metastasis of a cancer?

 

MPI 11.2: Are there "turning points” (hallmarks) during cancer progression which can be identified for therapeutic manipulation?

 

MPI 11.3: How do tumour cells transmit their epigenetic features to daughter cells and maintain the malignant phenotype?

 

MPI 11.4: How do dietary patterns and eating behaviours influence bariatric surgery outcomes?

 

MPI 11.5: Why is health literacy an integral component in improving cancer care?

 

MPI 11.6: What efforts are being done to increase diversity and representation in medical school?

 

MPI 11.7: How does the integration of nanotechnology with wearable devices and sensors contribute to real-time monitoring of health parameters and disease management?

 

MPI 11.8: How can nanomaterials and nanosensors be employed for early disease detection and diagnostics, such as in the case of cancer biomarkers?

 

MPI 11.9: What are the environmental implications of nanotechnology in life sciences, particularly concerning the disposal and impact of nanomaterials in the environment?

 

MPI 11.10: How long before a gastroscopy should patients stop using Ozempic to reduce the risk of aspiration?

 

MPI 11.11: How can we improve executive functioning?

 

MPI 11.12: How can we harness the therapeutic power of music for Parkinson’s disorder?

 

MPI 11.13: What are the current challenges and emerging solutions for severe traumatic brain injury?

 

MPI 11.14: How can e-health approaches best support individuals with mental illness and co-occurring substance use disorders?

 

MPI 11.15: How have ethical principles been incorporated/considered in transplant allocation systems?

 

MPI 11.16: Which prioritization strategies have been used in waitlist management? (The student can choose an area, e.g., cardiology, ophthalmology, orthopedics etc)

 

MPI 11.17: What’s the peri-implant bone healing procedure?

 

MPI 11.18: What are the complications after dental implant surgery?

 

MPI 11.19: What are the current methodologies to prevent peri-implantitis?

 

MPI 11.20: How do macrophages contribute to metabolic diseases and are these cells suitable therapeutic targets? (Can be a literature review or research proposal on targeting macrophages to combat a particular metabolic disease)

 

MPI 11.21: Clearance of senescent β-cells to prevent diabetes progression: should we eliminate the cells most therapeutic approaches aim to preserve?

 

MPI 11.22: How can we target/utilize the innate immune system to control/destroy the tumor microenvironment?

 

MPI 11.23: Why may some cancers respond better to certain cancer treatments than other cancers, and the direction of personalized treatment in cancer therapy?

 

MPI 11.24: Propose a novel strategy (i.e., new technology) using microbiota to treat Crohn's disease.

 

MPI 11.25: What is the role of ICAM1 on immune cells in glioblastoma?

 

MPI 11.26: How can ICAM1 be used as a therapeutic target for glioblastoma?

 

MPI 11.27: What are the quality improvement initiatives and interventions targeting or supporting postoperative handovers to the ICU? (Systematic Review)

 

MPI 11.28: What types of quality improvement or redesign initiatives targeting surgical safety checklists (SSCs) currently exist in the literature? This would be a systematic review.

 

MPI 11.29: How promising is the utilization of biomarkers in the diagnosis of cancer?

 

MPI 11.30: What is the potential of biomarkers in diagnosing depression?

 

MPI 11.31: Bone metastases commonly occur in those with prostate cancer and breast cancer. What makes the bone a favourable site for metastatic bone disease and what therapies have been developed to mitigate some of these effects?

 

MPI 11.32: Perhaps one of the most challenging tasks for scientists is developing in vitro models to describe in vivo processes. One new field of interest is the development of organ-on-a-chip models, what are the advantages and limitations of such models?

 

MPI 11.33: Circular RNA has recently been suggested as a potential therapeutic for the treatment of a variety of disease. In what ways can they be utilized as potential therapeutics for cancer?   

 

MPI 11.34: How do epigenetic changes affect differentiation during hematopoiesis?

 

MPI 11.35: How does transcription factor dysregulation result in leukemogenesis? How does this apply to pre-leukemic stem cells?

 

MPI 11.36: How does the bone marrow microenvironment support leukemia? And does it play a role in measurable residual disease (MRD)?

 

MPI 11.37: What are hypothesized the multiscale mechanisms of depression, and how do they relate? (Literature review of gene, cell, circuit, network, and symptom levels)

 

MPI 11.38: What are the current state- and location-specific EEG/ECOG/MEG biomarkers of depression?

 

MPI 11.39: What factors contribute to health inequalities among new immigrants in Canada? How can these disparities be reduced or eliminated?

 

MPI 11.40: What is the relationship between lifestyle factors, such as diet, physical activity and cognitive engagement and the risk of developing Alzheimer's disease.

 

MPI 11.41: How does immunomodulation impact patient outcomes in islet cell transplantation for Type 1 diabetes. What are the key factors influencing the success and long-term efficacy of this approach?

 

MPI 11.42: What are the advantages and drawbacks of organoids as in vitro models?

 

MPI 11.43: Discuss the process of breast cancer cell intravasation and its significance.

 

MPI 11.44: Can the properties of composite materials be enhanced through the use of recycled fibers as additives, potentially reducing the reliance on metals in various applications?

 

MPI 11.45: Is it possible to study and enhance metallic or polymer composites for the infantry (on-ground soldiers) or military?

 

MPI 11.46: How can we manufacture and deploy bio-inspired energy absorption materials for medical applications?

 

MPI 11.47: Can we use reliability & quality control tools alongside artificial intelligence in manufacturing?

 

MPI 11.48: Can 3D printing become a mainstream technique in various industries by identifying areas where it can replace traditional methods, such as in medicine, agriculture, mining, and heavy industrial manufacturing, while also exploring sustainability aspects?

 

MPI 11.49: How does adolescent cannabis use affect susceptibility to schizophrenia?

 

MPI 11.50: How does prenatal nicotine exposure affect short-term and long-term memory?

 

MPI 11.51: How does chronic stress exposure compared to acute stress exposure affect susceptibility to alcohol abuse?

 

MPI 11.52: How does hypoxia impact cancer progression?

 

MPI 11.53: What is trained immunity and how is it relevant to immunotherapy?

 

MPI 11.54: How can machine learning be used to analyze hospital/patient data? For example, predicting ICU stay length, lung cancer based on different variables, etc.

 

MPI 11.55: How can molecular cloning be used to confirm or test foreign gene function in transgenic Arabidopsis plants?

 

MPI 11.56: Females are at a greater risk of Osteoarthritis than males, although many animal studies are performed in young male mice. Is the use of mostly male mice a limitation in the field?

 

MPI 11.57: Small animal models are commonly used in Osteoarthritis research to determine therapeutic targets. How can researches assess pain in these models?

 

MPI 11.58: Design a study comparing various Osteoarthritis mouse models (ie. genetic, sex, traumatic, etc) to analyze if there is a significant difference.

 

MPI 11.59: The APOBEC3 family of genes function in the innate immune system. What possible roles do these genes play in cancer formation?

 

MPI 11.60: Mutagenic processes leave “footprints” within cancer genomes referred to as “mutational signatures”. What do the mutational signatures that are prevalent in breast cancer tell us about the possible etiology of the disease?

 

MPI 11.61: HER2 positive subtype tumors make up approximately 20% of all breast cancer cases. Discuss the mouse model(s) that exist for study of HER2+ breast cancer and to what degree they effectively model the human disease.